MENU
+Compare
BIIB
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$118.39
Change
+$1.18 (+1.01%)
Capitalization
31.34B

BIIB Biogen Forecast, Technical & Fundamental Analysis

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan... Show more

Industry: #Biotechnology
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for BIIB with price predictions
May 07, 2025

BIIB's RSI Indicator recovers from oversold territory

The RSI Oscillator for BIIB moved out of oversold territory on April 14, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In of the 39 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on April 23, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BIIB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BIIB broke above its upper Bollinger Band on May 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BIIB entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.110) is normal, around the industry mean (5.632). P/E Ratio (26.955) is within average values for comparable stocks, (48.974). BIIB's Projected Growth (PEG Ratio) (8.807) is slightly higher than the industry average of (3.004). Dividend Yield (0.000) settles around the average of (0.161) among similar stocks. P/S Ratio (3.181) is also within normal values, averaging (3.643).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

View a ticker or compare two or three
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

BIIB is expected to report earnings to rise 34.11% to $4.05 per share on July 23

Biogen BIIB Stock Earnings Reports
Q2'25
Est.
$4.05
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.31
Q2'24
Beat
by $1.27
The last earnings report on May 01 showed earnings per share of $3.02, beating the estimate of $2.96. With 1.87M shares outstanding, the current market capitalization sits at 31.34B.
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7570
Web
https://www.biogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IIIN35.470.73
+2.10%
Insteel Industries
ABM50.770.92
+1.85%
ABM Industries
CNF0.72-0.01
-0.74%
CNFinance Holdings Limited
FOXA50.42-0.39
-0.77%
Fox Corp
OXBR1.44-0.07
-4.76%
Oxbridge Re Holdings Limited

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+1.01%
AMGN - BIIB
48%
Loosely correlated
-1.37%
NVS - BIIB
47%
Loosely correlated
-1.41%
PFE - BIIB
45%
Loosely correlated
+0.79%
SNY - BIIB
39%
Loosely correlated
-0.27%
AZN - BIIB
39%
Loosely correlated
-3.95%
More